IL1RL2 and psoriasis 14, pustular: Spesolimab, an IL-36 receptor inhibitor, has demonstrated efficacy and safety in rapidly controlling acute GPP episodes through Phase II clinical trials,3 making it a promising therapeutic option for GPP management.